Inspire Medical Systems (NYSE:INSP) vs. Regenicin (OTCMKTS:RGIN) Head to Head Comparison

Regenicin (OTCMKTS:RGIN) and Inspire Medical Systems (NYSE:INSP) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership.

Volatility and Risk

Regenicin has a beta of -18.99, meaning that its stock price is 1,999% less volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500.

Earnings and Valuation

This table compares Regenicin and Inspire Medical Systems”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regenicin	N/A	N/A	-$640,000.00	N/A	N/A
Inspire Medical Systems	$624.80 million	9.45	-$21.15 million	$1.07	185.14

Regenicin has higher earnings, but lower revenue than Inspire Medical Systems.

Institutional and Insider Ownership

0.0% of Regenicin shares are held by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are held by institutional investors. 4.1% of Inspire Medical Systems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Regenicin and Inspire Medical Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Regenicin	N/A	N/A	N/A
Inspire Medical Systems	4.37%	5.51%	4.74%

Analyst Ratings

This is a summary of recent ratings for Regenicin and Inspire Medical Systems, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regenicin	0	0	0	0	0.00
Inspire Medical Systems	0	4	8	0	2.67

Inspire Medical Systems has a consensus price target of $227.75, suggesting a potential upside of 14.97%. Given Inspire Medical Systems’ stronger consensus rating and higher probable upside, analysts clearly believe Inspire Medical Systems is more favorable than Regenicin.

Summary

Inspire Medical Systems beats Regenicin on 10 of the 11 factors compared between the two stocks.

About Regenicin

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.

About Inspire Medical Systems

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.